Barclays
BEAM icon

Barclays’s Beam Therapeutics BEAM Stock Holding History

Barclays’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$735K – 5274
2024
Q3 		$735K Sell
30,000
-14,000
-32% -$362K ﹤0.01% 3550
2024
Q2 		$1.03M Sell
44,000
-3,000
-6% -$73.7K ﹤0.01% 2582
2024
Q1 		$1.55M Buy
+47,000
New +$1.46M ﹤0.01% 2774

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Barclays's BEAM Position: Q2 2026 in Review

Barclays increased its Beam Therapeutics (BEAM) stake by 47% in Q2 2026, buying an estimated $682K and bringing the position to 70,219 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Barclays first reported a position in BEAM in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.6M in Q2 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Barclays held 70,219 shares of Beam Therapeutics worth $2.41M as of Q2 2026.
  • Barclays bought 22,581 Beam Therapeutics shares in Q2 2026, an estimated $682K.
  • Beam Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2238 holding.
  • Barclays first reported a position in Beam Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Beam Therapeutics position peaked at $11.6M in Q2 2025.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.